Last Updated: November 13, 2026

Rhodes Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for RHODES PHARMS

RHODES PHARMS has twenty-nine approved drugs.

There are two tentative approvals on RHODES PHARMS drugs.

Summary for Rhodes Pharms

US Patents:	0
Tradenames:	21
Ingredients:	19
NDAs:	29

Drugs and US Patents for Rhodes Pharms

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rhodes Pharms	VARENICLINE TARTRATE	varenicline tartrate	TABLET;ORAL	213268-002	May 21, 2025		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Rhodes Pharms	METHYLPHENIDATE HYDROCHLORIDE	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	214111-002	May 31, 2022		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Rhodes Pharms	OXYCODONE AND ACETAMINOPHEN	acetaminophen; oxycodone hydrochloride	TABLET;ORAL	201278-001	Aug 28, 2014	AA	RX	No	No		⤷ Start Trial				⤷ Start Trial
Rhodes Pharms	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	TABLET;ORAL	213111-007	Jan 13, 2021	AB	RX	No	No		⤷ Start Trial				⤷ Start Trial
Rhodes Pharms	DILAUDID	hydromorphone hydrochloride	TABLET;ORAL	019892-003	Nov 9, 2007	AB	RX	Yes	No		⤷ Start Trial				⤷ Start Trial
Rhodes Pharms	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	TABLET;ORAL	213111-003	Jan 13, 2021	AB	RX	No	No		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Rhodes Pharms

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-007	Apr 17, 2015	10,463,624	⤷ Start Trial
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-001	Apr 17, 2015	10,463,624	⤷ Start Trial
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-004	Apr 17, 2015	10,463,624	⤷ Start Trial
Rhodes Pharms	DILAUDID	hydromorphone hydrochloride	TABLET;ORAL	019892-002	Nov 9, 2007	6,589,960	⤷ Start Trial
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-006	Apr 17, 2015	10,463,624	⤷ Start Trial
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-003	Apr 17, 2015	10,463,624	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for RHODES PHARMS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Capsules	10 mg	➤ Subscribe	2015-12-24
➤ Subscribe	Extended-release Capsules	30 mg	➤ Subscribe	2016-03-28
➤ Subscribe	Injection	2 mg/mL	➤ Subscribe	2011-06-22
➤ Subscribe	Extended-release Capsules	60 mg	➤ Subscribe	2015-12-23
➤ Subscribe	Extended-release Capsules	15 mg, 20 mg, 40 mg and 50 mg	➤ Subscribe	2015-12-28
➤ Subscribe	Oral Solution	5 mg/5mL	➤ Subscribe	2011-02-25
➤ Subscribe	Tablets	2 mg, 4 mg, and 8 mg	➤ Subscribe	2013-08-05

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.